Advanced Solid Cancer Clinical Trial
Official title:
A Phase I, Open-label Study to Assess the Safety and Tolerability of Ascending Doses of SH-1028 Tablets in Patients With Advanced Solid Cancer
This is a Phase 1, open-label study of SH-1028 with dose escalation cohorts in locally advanced solid cancer patients who have progressed following prior therapy with an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKI) agent or standard treatment.
The study is designed to evaluate safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of once-daily and orally (PO) administered SH-1028 tablets. The overall study design is shown in the flow chart below. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01416623 -
A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Recruiting |
NCT03917043 -
APG-2449 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03884517 -
Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer
|
Phase 1 | |
| Recruiting |
NCT03791112 -
A Phase I Study of BPI-16350 in Patients With Advanced Solid Tumor
|
Phase 1 | |
| Recruiting |
NCT04877717 -
A Study of SHR-A1904 in Patients With Advanced Solid Cancer
|
Phase 1 | |
| Recruiting |
NCT05770310 -
A Phase I Study Of JS015 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05947474 -
ORB-011 In Patients With Advanced Solid Tumors
|
Phase 1 |